Minor use permit for praziquantel for non-Seriola finfish
Ectoparasite infections are major production limiting issues in aquaculture. The only products permitted for use in Australia against ectoparasites of finfish are formalin, sodium percarbonate and hydrogen peroxide. These products can have negative effects on fish gills and skin and result in direct mortality when elevated chemical dose or duration of exposure are sub-optimal or improperly calculated. Against some flatworm parasites formalin, sodium percarbonate and hydrogen peroxide have low efficacy. Praziquantel (PZQ) immersion treatments have been found to be both safe and efficacious for current fish flatworms applications, at a low dosage and duration of exposure, with a lesser or equivalent environmental impact. The aquaculture industry and the Subcommittee for Aquatic Animal Health identified access to PZQ for finfinfish as a priority. Treatment forms a vital part of parasite management in aquaculture along with husbandry practices designed to interrupt parasite lifecycles. Appropriate use of PZQ can help alleviate reduced growth and food conversion and improves welfare associated with flatworm parasite infestation. A permit obtained as part of this project will facilitate better parasite management, improve production and fish welfare. APVMA provided pre-application advice on PZQ. Available data for PZQ can satisfy the APVMA module requirements for efficacy, chemistry and manufacture, toxicology, trade and occupational health and safety. These are available in published literature, a range of industry studies of animals treated off-label and laboratory studies. There is a lack of data to satisfy the requirements mainly in the environment modules and the target animal safety module.
PZQ is registered as an active ingredient, and for use in cats, dogs, horses, cattle, pigs and sheep in Australia. An unregistered product is manufactured by VetLab Autopak into two permitted products for use in kingfish as an in-feed (PER#87336) or immersion (PER#87833) treatments. The APVMA PAA assessed PZQ as suitable for assessment for use in finfish.
Minor use permit for oxytetracycline in non-salmonid finfish
Development of a national sector-specific biosecurity plan guideline and template for the sea-cage finfish (non-salmonid) industry of Australia.
Evaluation of Cobia and Giant Groper production and health in multiple growout systems, as an alternative species to farm in WSSV affected areas of South East Queensland
Optimisation of treatment of Cryptocaryon irritans in Barramundi aquaculture
Significant losses of farmed barramundi have occurred in coastal marine aquaculture sites utilising marine water sources due to Cryptocaryon irritans infestations. The disease costs have had substantial impacts on commercial aquaculture operations. Cryptocaryon irritans has a direct life cycle with an adult in the skin or gills of the fish and asexual reproduction in the environment away from the fish. The life cycle of C. irritans is temperature and host dependant and treatment must be timed with critical phases of the life history to maximise efficacy. This project will establish this timing to provide guidelines for optimised treatment.
The existing treatments have substantial costs ($3K+/treatment) and a sub-optimal profile for environmental release with high toxicity and environmental persistence. This project will optimise doses of existing treatments, and identify and assess new treatments. Products identified as effective and safe will have optimised guidelines developed for delivery to ensure the best outcome for farms and the environment. Such improvements will support further expansion of the finfish aquaculture industry in Northern Australia.